ʻO Kina nā lāʻau lapaʻau maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi

# Kina Ke ulu mau nei nā lāʻau lapaʻau hou no ka maʻi maʻi maʻi ʻaʻai liʻiliʻi ʻole (NSCLC) ma Kina. Hāʻawi kēia ʻatikala i kahi ʻike o nā holomua hou loa, e kālele ana i nā lāʻau lapaʻau i hoʻopaʻa ʻia, immunotherapies, a me nā ala ʻē aʻe i loaʻa i nā maʻi. E ʻimi mākou i ka ʻāina o ʻO Kina nā lāʻau lapaʻau maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi, e hōʻike ana i nā manaʻo nui no nā maʻi a me nā mea mālama.

ʻO nā Therapies i hoʻopaʻa ʻia no NSCLC ma Kina

Hōʻike nā lāʻau lapaʻau i kahi holomua nui ma ʻO Kina nā lāʻau lapaʻau maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi. Kuhi ʻia kēia mau lāʻau lapaʻau i nā mutation genetic e alakaʻi ana i ka ulu ʻana o nā maʻi kanesa. Ua hōʻike ʻia kekahi mau lāʻau lapaʻau i manaʻo ʻia i ka maikaʻi i ka hoʻonui ʻana i ke ola a me ka hoʻomaikaʻi ʻana i ka maikaʻi o ke ola no nā poʻe maʻi me nā hoʻololi kikoʻī.

ʻO nā mea pale EGFR

ʻO ka hoʻololi ʻana o ka Epidermal growth factor receptor (EGFR) ka mea maʻamau i ka NSCLC, ʻoi aku ka nui o nā maʻi i puhi ʻole. Nui nā EGFR tyrosine kinase inhibitors (TKIs), e like me gefitinib, erlotinib, afatinib, osimertinib, a me nā mea ʻē aʻe, i loaʻa ma Kina a ua hōʻike i ka pono nui i ka mālama ʻana i ka NSCLC-mutated EGFR. Hana kēia mau lāʻau lapaʻau ma ke kāohi ʻana i ke ala hōʻailona EGFR, pale i ka ulu ʻana o ka maʻi tumora. ʻO ke koho ʻana o EGFR-TKI kikoʻī e pili ana i nā mea e like me ke ʻano o ka mutation EGFR a me ke olakino holoʻokoʻa o ka mea maʻi. ʻOkoʻa ka hopena a me nā hopena ʻaoʻao ma waena o kēia mau lāʻau.

ʻO nā mea pale ALK

ʻO ka hoʻoponopono hou ʻana o ka lymphoma kinase (ALK) anaplastic kekahi mea maʻamau maʻamau i ka NSCLC. ʻO nā mea pale ALK, e like me crizotinib, ceritinib, alectinib, a me brigatinib, e kuhikuhi pono i kēia hoʻololi. E like me nā TKI EGFR, ke koho ʻana i kahi mea hoʻopale ALK kūpono e noʻonoʻo i nā mea e like me ka hoʻonohonoho hou ʻana o ALK a me nā ʻano maʻi.

ʻO nā lāʻau lapaʻau ʻē aʻe

Ma waho aʻe o ka EGFR a me ka ALK inhibitors, loaʻa nā lāʻau lapaʻau ʻē aʻe ma Kina no nā maʻi NSCLC me nā hoʻololi genetic kikoʻī. Hoʻopili kēia i nā lāʻau lapaʻau e kuhikuhi ana i nā mutation ma ROS1, RET, a me BRAF, a me nā mea ʻē aʻe. Hiki ke ʻokoʻa ka loaʻa a me ka loaʻa ʻana o kēia mau lāʻau lapaʻau ma waena o Kina. He mea koʻikoʻi ka noho ʻana ma o ke kūkākūkā ʻana me nā oncologists no ke komo ʻana i kēia mau koho holomua.

Immunotherapy no NSCLC ma Kina

Hoʻohana ka Immunotherapy i ka mana o ka ʻōnaehana pale o ke kino e hakakā ai i ka maʻi kanesa. Hōʻike kēia ala i kahi hoʻololi paradigm i loko ʻO Kina nā lāʻau lapaʻau maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi a ua hōʻike i ka holomua kupaianaha i ka hoʻomaikaʻi ʻana i nā hopena ola no nā maʻi he nui.

Nā mea hoʻopaʻa hoʻopaʻa kino

ʻO ka Immune Checkpoint Inhibitors (ICIs) kahi papa o nā lāʻau lapaʻau immunotherapy e ālai ana i nā protein e kōkua ana i nā maʻi maʻi e pale aku i ka ʻōnaehana pale. ʻElua mau pahuhopu nui no nā ICI i hoʻolālā ʻia i ka make-1 (PD-1) a me ka programmed death-ligand 1 (PD-L1). ʻO Pembrolizumab, nivolumab, a me sintilimab nā hiʻohiʻona o ka PD-1 / PD-L1 inhibitors i ʻae ʻia ma Kina no NSCLC. Hoʻohana pinepine ʻia ka hoʻohana ʻana i nā ICI e nā pae hōʻike PD-L1 i loko o ka ʻōpū, ʻoiai ʻoi aku ka maikaʻi ma mua o ke kūlana PD-L1 i kekahi mau hihia. He mea koʻikoʻi ka nānā pono ʻana i nā hopena ʻaoʻao.

Nā Hana Hou ʻē aʻe

Ke hoʻomau nei ka noiʻi ʻana i ka hana hou i nā lāʻau lapaʻau NSCLC. ʻO nā lāʻau lapaʻau hou, me nā lāʻau lapaʻau i hoʻopaʻa ʻia e kūʻē i nā biomarkers e kū mai ana, ka hui pū ʻana o ka immunotherapy me ka lāʻau lapaʻau i hoʻopaʻa ʻia, a me nā ala hou ʻē aʻe, ke hoʻokolokolo ʻia nei a ke hoʻomaka nei e hana i ka hopena i ka hana lapaʻau. Ke ulu wikiwiki nei ke kahua, a he mea nui ke kūkākūkā maʻamau me nā mea mālama olakino kūikawā no ka hoʻomau ʻana i nā mea hou loa. No ka ʻike pololei a hou, e ʻoluʻolu e nīnau i kāu kauka.

Ke koho ʻana i ka Lapaʻau Pono

ʻO ke ala lapaʻau maikaʻi loa no NSCLC ma Kina he mea pilikino a hilinaʻi ʻia i nā kumu he nui e pili ana i ka pae o ka maʻi kanesa, nā genetic mutations i kēia manawa, ke olakino holoʻokoʻa o ka mea maʻi, a me ka loaʻa ʻana o nā lāʻau lapaʻau. He mea koʻikoʻi nā kūkākūkā me kahi kanaka oncologist loea i ka maʻi ʻaʻai māmā no ka hoʻoholo ʻana i ka hoʻolālā lapaʻau kūpono loa. ʻO ka Shandong Baofa Cancer Research Institute (https://www.baofahospital.com/) he keʻena alakaʻi ma Kina e hāʻawi ana i ka mālama maʻi maʻi holomua.

Lapaʻau ʻaoʻao hopena a me ka hooponopono

Nui nā lāʻau lapaʻau maʻi maʻi, me nā mea no ka NSCLC, hiki ke loaʻa nā hopena ʻaoʻao. ʻOkoʻa kēia mau hopena ʻaoʻao ma muli o ka lāʻau lapaʻau kūikawā a me ka mea maʻi hoʻokahi. He mea koʻikoʻi ke kamaʻilio wehe ʻana me kāu hui mālama ola e pili ana i nā hopena ʻaoʻao no ka mālama pono ʻana iā lākou. Loaʻa nā lawelawe kākoʻo a me nā hoʻolālā no ka mālama ʻana i nā hopena ʻaoʻao e hōʻoia i ka hōʻoluʻolu a me ka maikaʻi o ke ola i ka wā mālama.

Ka hopena

ʻO ka ʻāina o ʻO Kina nā lāʻau lapaʻau maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi he ikaika a hoʻohiki. ʻO ka holomua o ka lāʻau lapaʻau, immunotherapy, a me nā ala ʻē aʻe e hāʻawi i ka manaolana no nā maʻi. He mea koʻikoʻi ka ʻike mua ʻana a me ka hōʻoia koke ʻana no ka loaʻa ʻana o nā koho lapaʻau kūpono loa. He mea nui ka hana pū me kāu hui mālama ola e hoʻokele i nā paʻakikī o ka mālama ʻana i ka NSCLC a hoʻonui i kou manawa kūpono o nā hopena kūleʻa. E hoʻomanaʻo e kūkākūkā me kāu kauka oncologist e kūkākūkā i nā holomua hou loa a me ka hoʻolālā lapaʻau maikaʻi loa no kāu kūlana kikoʻī.